Windtree Therapeutics Has Been Granted U.S. Patent Number 11,583,540 Titled “Istaroxime-Containing Intravenous Formulation For The Treatment Of Acute Heart Failure”
https://ppubs.uspto.gov/pubwebapp/external.html?q=(11583540).pn
Why Chemomab Therapeutics Shares Are Trading Higher Today
Chemomab Therapeutics Ltd (NASDAQ: CMMB) shares are trading higher on Tuesday after the company announced FDA clearance of its Investigational New Drug Application to evaluate CM-101 in a Phase 2 trial in
Analyst Says Ionis’ Additional Hereditary Angioedema Study Data Supports ‘Highly Competitive Profile’
Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced additional interim data from a Phase 2 open-label extension (OLE) study of donidalorsen for hereditary angioedema. …
Aileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fall
Aileron Therapeutics (NASDAQ:ALRN) announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in p53-mutated breast…
Merck’s COVID-19 Treatment Fails To Prevent Infection In Household Exposure
Merck & Co Inc (NYSE:MRK) Lagevrio (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household…
Corvus Pharma’s HIV Candidate Shows Potential To Prevent Virus Re-Emergence
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) announced new data demonstrating the potential of CPI-818, an ITK inhibitor, to reduce the need for chronic…
FDA Gives Green Signal To Chemomab Therapeutics’ Rare Disease Study
The FDA has signed off Chemomab Therapeutics Ltd’s (NASDAQ:CMMB) Investigational New Drug (IND) Application to evaluate CM-101 in a Phase 2…
Why Are Apellis Pharmaceuticals Shares Trading Higher Today?
The FDA approved Apellis Pharmaceuticals Inc’s (NASDAQ:APLS) Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Syfovre…
Why CVRx Stock Is Plunging Today
CVRx Inc (NASDAQ:CVRX) announced the preliminary topline results of the BeAT-HF (Baroreflex Activation Therapy for Heart Failure) post-market randomized clinical trial.…
TC BioPharm Announces Publication Of Paper In AML Research Highlighting The Company’s Development Of Allogeneic Gamma-Delta T Cell Therapies
TC BioPharm(Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer,